Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
People with neurodegeneration but not brain amyloid surface in two new studies of preclinical AD, suggesting this odd population is both legitimate and potentially large.
Researchers can vote for the winner of this year’s Geoffrey Beene NeuroDiscovery Challenge.
A repeat expansion that causes neurodegenerative disease is transcribed both forward and backward, producing sense and antisense RNAs and multiple polypeptides.
Some neurons stand out in the crowd. Researchers report that genomic variation among neurons in the brain is more common than originally thought.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
More evidence that an antisense RNA strategy might work for certain types of ALS and FTD.
Screens of yeast and human-derived neurons uncover reasons for α-synuclein toxicity and potential ways to prevent it.
A meta-analysis of four large genome-wide association studies turned up 11 new risk genes for Alzheimer’s disease.
Deep brain stimulation restores walking and swimming abilities in rats with spinal injuries, so long as a few nerve fibers remain intact.
Two studies strengthen the link between shut-eye and Alzheimer’s disease, and a mouse analysis of how the brain drains waste offers insight into the connection.
An astrocyte protein stymies toxic interplay between Aβ oligomers and prion proteins.
Among cognitively healthy older adults, the rate of change in cerebrospinal fluid biomarkers helps predict who will develop Alzheimer’s disease.
Silencing aberrant C9ORF72 mRNA helps normalize pathology in neurons, suggesting the transcripts are toxic to the cells.
A cancer drug-turned-Alzheimer’s prospect now appears to have potential against a third disease, reportedly protecting animal models from Parkinson’s damage.